Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
84.1 kDa. DTT-reduced protein migrates as 100-110 kDa protein due to glycosylation
HEK 293 Cells
Greater than 95% by SDS-PAGE
Measured by its ability to inhibit the VEGF dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is typically 9-20 ng/ml in the presence of 5 ng/ml rhVEGF165.
Less than 1.0 EU/µg protein (determined by LAL method).
Lyophilized from PBS, pH 7.4, 5-8% mannitol or trehalose
Centrifuge the vial before opening. Reconstitute in sterile PBS, pH 7.4 to 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, store at -20°C.
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD.